DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
PAT
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
PAT
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NELOTANSERIN
2
Small molecule
Investigational
Unknown
Unknown
Hallucinations; Lewy Body Disease; Sleep Initiation and Maintenance Disorders
Serotonin 2a (5-HT2a) receptor inverse agonist
NELOTANSERIN
×
Maximum Phase:
2
First Approval:
None
UNII:
4ZA73QEW2P
Molecule Type:
Small molecule
Molecular Formula:
C18H15BrF2N4O2
Molecular Weight:
437.24
AlogP:
4.78
PSA:
68.18
HBD:
2.0
HBA:
#RotB:
4.0
Source:
ENMD-981693
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Pancreatic Neoplasms
Fibroblast growth factor receptor inhibitor
ENMD-981693
×
Maximum Phase:
2
First Approval:
None
UNII:
DNZ11VPY7Q
Molecule Type:
Small molecule
Molecular Formula:
C22H16N4O4
Molecular Weight:
400.39
AlogP:
3.15
PSA:
99.17
HBD:
1.0
HBA:
#RotB:
3.0
Source:
LY2940094
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Alcoholism; Depressive Disorder, Major
Nociceptin receptor antagonist
LY2940094
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-275183
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung
Tubulin stabiliser
BMS-275183
×
Maximum Phase:
2
First Approval:
None
UNII:
UQC681JJIV
Molecule Type:
Small molecule
Molecular Formula:
C43H59NO16
Molecular Weight:
845.94
AlogP:
3.72
PSA:
239.75
HBD:
4.0
HBA:
#RotB:
8.0
Source:
MITOGLITAZONE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Diabetes Mellitus, Type 2
Unknown
MITOGLITAZONE
×
Maximum Phase:
2
First Approval:
None
UNII:
29I7RP18RG
Molecule Type:
Small molecule
Molecular Formula:
C19H18N2O4S
Molecular Weight:
370.43
AlogP:
2.8
PSA:
85.36
HBD:
1.0
HBA:
#RotB:
7.0
Source:
ABRILUMAB
2
Antibody
Investigational
Unknown
Unknown
Colitis, Ulcerative; Crohn Disease
Integrin alpha-4/beta-7 inhibitor
ABRILUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
Y9UQ37XT2T
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BGC-20-1531 FREE BASE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BGC-20-1531 FREE BASE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C26H24N2O6S
Molecular Weight:
492.55
AlogP:
4.66
PSA:
107.73
HBD:
1.0
HBA:
#RotB:
8.0
Source:
AD-159
2
Antibody
Investigational
Unknown
Unknown
Unknown
Envelope glycoprotein gp160 inhibitor
AD-159
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MARDEPODECT
2
Small molecule
Investigational
Unknown
Unknown
Huntington Disease; Schizophrenia
Unknown
MARDEPODECT
×
Maximum Phase:
2
First Approval:
None
UNII:
R9Y8EY0G42
Molecule Type:
Small molecule
Molecular Formula:
C25H20N4O
Molecular Weight:
392.46
AlogP:
5.28
PSA:
52.83
HBD:
0.0
HBA:
#RotB:
5.0
Source:
RG-547
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Cyclin-dependent kinase 1 inhibitor
RG-547
×
Maximum Phase:
2
First Approval:
None
UNII:
T61871RKRI
Molecule Type:
Small molecule
Molecular Formula:
C18H21F2N5O4S
Molecular Weight:
441.46
AlogP:
1.41
PSA:
127.51
HBD:
2.0
HBA:
#RotB:
6.0
Source:
CENDERITIDE
2
Protein
Investigational
Unknown
Unknown
ST Elevation Myocardial Infarction; Heart Failure
Unknown
CENDERITIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
9NKZ9LYZ06
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CBX-129801
2
Unknown
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 1; Diabetic Neuropathies
Unknown
CBX-129801
×
Maximum Phase:
2
First Approval:
None
UNII:
IF95YG4W0P
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BOS-589
2
Unknown
Investigational
Unknown
Unknown
Irritable Bowel Syndrome
Tyrosine-protein kinase receptor RET inhibitor
BOS-589
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TGN-1412
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Neoplasms; Psoriasis; Lupus Erythematosus, Systemic
T-cell-specific surface glycoprotein CD28 agonist
TGN-1412
×
Maximum Phase:
2
First Approval:
None
UNII:
POO0DOD3AS
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELSUBRUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Erythematosus, Systemic
Tyrosine-protein kinase BTK inhibitor
ELSUBRUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
1487U1Q3IQ
Molecule Type:
Small molecule
Molecular Formula:
C17H19N3O2
Molecular Weight:
297.36
AlogP:
2.16
PSA:
79.19
HBD:
2.0
HBA:
#RotB:
3.0
Source:
ALPHA CYCLODEXTRIN
2
Oligosaccharide
Investigational
Unknown
Unknown
Unknown
Unknown
ALPHA CYCLODEXTRIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Oligosaccharide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FOSBRETABULIN
2
Small molecule
Investigational
Unknown
Unknown
Ovarian Neoplasms; Neoplasms; Neuroendocrine Tumors; Thyroid Neoplasms
Unknown
FOSBRETABULIN
×
Maximum Phase:
2
First Approval:
None
UNII:
I5590ES2QZ
Molecule Type:
Small molecule
Molecular Formula:
C18H21O8P
Molecular Weight:
396.33
AlogP:
3.36
PSA:
103.68
HBD:
2.0
HBA:
#RotB:
8.0
Source:
PARSATUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung
Epidermal growth factor-like protein 7 inhibitor
PARSATUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
435M4HCP2M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ACOZIBOROLE
2
Small molecule
Investigational
Unknown
Unknown
Trypanosomiasis, African
Cleavage and polyadenylation specificity factor subunit inhibitor
ACOZIBOROLE
×
Maximum Phase:
2
First Approval:
None
UNII:
2IOR2OO3GW
Molecule Type:
Small molecule
Molecular Formula:
C17H14BF4NO3
Molecular Weight:
367.11
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
L-DOS47
2
Unknown
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms; Adenocarcinoma of Lung
Unknown
L-DOS47
×
Maximum Phase:
2
First Approval:
None
UNII:
95E1ZQM329
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
7-METHYLXANTHINE
2
Small molecule
Investigational
Unknown
Unknown
Myopia
Unknown
7-METHYLXANTHINE
×
Maximum Phase:
2
First Approval:
None
UNII:
E9M81NJM6G
Molecule Type:
Small molecule
Molecular Formula:
C6H6N4O2
Molecular Weight:
166.14
AlogP:
-0.23
PSA:
84.06
HBD:
2.0
HBA:
#RotB:
0.0
Source:
ASUNERCEPT
2
Protein
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Glioblastoma; Severe Acute Respiratory Syndrome
Tumor necrosis factor ligand superfamily member 6 binding agent
ASUNERCEPT
×
Maximum Phase:
2
First Approval:
None
UNII:
F333OQQ9UV
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DELPAZOLID
2
Small molecule
Investigational
Unknown
Unknown
Tuberculosis, Pulmonary
Bacterial 70S ribosome inhibitor
DELPAZOLID
×
Maximum Phase:
2
First Approval:
None
UNII:
43EP6XV33E
Molecule Type:
Small molecule
Molecular Formula:
C14H17FN4O3
Molecular Weight:
308.31
AlogP:
0.84
PSA:
68.61
HBD:
1.0
HBA:
#RotB:
3.0
Source:
BMX-010
2
Unknown
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 1; Acne Vulgaris; Dermatitis, Atopic; Psoriasis; Rosacea
Unknown
BMX-010
×
Maximum Phase:
2
First Approval:
None
UNII:
BN93L2NT5I
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MOXAVERINE
2
Small molecule
Investigational
Unknown
Unknown
Digestive System Diseases; Ischemia
Unknown
MOXAVERINE
×
Maximum Phase:
2
First Approval:
None
UNII:
P3P08Y1XJ4
Molecule Type:
Small molecule
Molecular Formula:
C20H21NO2
Molecular Weight:
307.39
AlogP:
4.41
PSA:
31.35
HBD:
0.0
HBA:
#RotB:
5.0
Source:
AZD0328
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Schizophrenia
Neuronal acetylcholine receptor protein alpha-7 subunit agonist
AZD0328
×
Maximum Phase:
2
First Approval:
None
UNII:
2B218X5QIY
Molecule Type:
Small molecule
Molecular Formula:
C13H16N2O
Molecular Weight:
216.28
AlogP:
1.48
PSA:
25.36
HBD:
0.0
HBA:
#RotB:
0.0
Source:
ISTIRATUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Pancreatic Neoplasms
Insulin-like growth factor I receptor inhibitor
ISTIRATUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
XLR461MD3M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CIBINETIDE
2
Protein
Investigational
Unknown
Unknown
Depressive Disorder
Unknown
CIBINETIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
9W5677JKDA
Molecule Type:
Protein
Molecular Formula:
C51H84N16O21
Molecular Weight:
1257.32
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
ORTATAXEL
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Renal Cell; Glioblastoma; Kidney Neoplasms; Lung Neoplasms; Lymphoma
Unknown
ORTATAXEL
×
Maximum Phase:
2
First Approval:
None
UNII:
8H61Y4E29N
Molecule Type:
Small molecule
Molecular Formula:
C44H57NO17
Molecular Weight:
871.93
AlogP:
3.66
PSA:
245.82
HBD:
3.0
HBA:
#RotB:
10.0
Source:
RELMAPIRAZIN
2
Small molecule
Investigational
Unknown
Unknown
Acute Kidney Injury
Unknown
RELMAPIRAZIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Q3UQB8PQ6H
Molecule Type:
Small molecule
Molecular Formula:
C12H16N6O8
Molecular Weight:
372.29
AlogP:
-4.01
PSA:
251.08
HBD:
8.0
HBA:
#RotB:
8.0
Source:
NT-501
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
NT-501
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BALICATIB
2
Small molecule
Investigational
Unknown
Unknown
Osteoarthritis; Osteoporosis
Cathepsin K inhibitor
BALICATIB
×
Maximum Phase:
2
First Approval:
None
UNII:
E00MVC7O57
Molecule Type:
Small molecule
Molecular Formula:
C23H33N5O2
Molecular Weight:
411.55
AlogP:
2.29
PSA:
88.47
HBD:
2.0
HBA:
#RotB:
7.0
Source:
LY-295501
2
Small molecule
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Unknown
LY-295501
×
Maximum Phase:
2
First Approval:
None
UNII:
240Y4YO0TN
Molecule Type:
Small molecule
Molecular Formula:
C15H12Cl2N2O4S
Molecular Weight:
387.24
AlogP:
3.44
PSA:
84.5
HBD:
2.0
HBA:
#RotB:
3.0
Source:
PRILIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell surface antigen CD4 negative modulator
PRILIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
176
177
178
179
180
181
182
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA